Urología
Especialidad
![Foto de Urología](/img/noimage.png)
![Foto de Hospital Clinic Barcelona](/img/noimage_org.png)
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (11)
2022
-
Non-metastatic castration-resistant prostate cancer: management recommendations
Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 193-213
2019
-
Bladder pain syndrome: Prevalence and routine clinical practice in women attending functional urology and urodynamics units in Spain
Actas Urologicas Espanolas, Vol. 43, Núm. 2, pp. 62-70
-
Cancer-Specific Survival Stratification Derived from Tumor Expression of Tissue Inhibitor of Metalloproteinase-2 in Non-Metastatic Renal Cell Carcinoma
Pathology and Oncology Research, Vol. 25, Núm. 1, pp. 289-299
2018
-
Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practice
Actas Urologicas Espanolas, Vol. 42, Núm. 4, pp. 238-248
2017
-
Consenso sobre el manejo del cáncer de próstata resistente a la castración avanzado en España
Archivos Espanoles de Urologia, Vol. 70, Núm. 9, pp. 777-791
-
Diagnosis and treatment for clinically localized prostate cancer. Adherence to the European Association of Urology clinical guidelines in a nationwide population-based study – GESCAP group
Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 359-367
2016
-
Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer
Critical Reviews in Oncology/Hematology, Vol. 100, pp. 127-136
-
Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study
International Urology and Nephrology, Vol. 48, Núm. 5, pp. 645-656
-
Tendencias de tratamiento en el cáncer de próstata clínicamente localizado. Análisis poblacional a nivel nacional: grupo GESCAP
Actas Urologicas Espanolas, Vol. 40, Núm. 4, pp. 209-216
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572